Savara Announces New Employment Inducement Grant
2023年8月5日 - 5:05AM
ビジネスワイヤ(英語)
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical
company focused on rare respiratory diseases, today announced the
grant of inducement awards to three new employees.
On August 3, 2023, the Compensation Committee of Savara's Board
of Directors granted the inducement awards to three new employees
who recently joined the Company. The inducement awards consist of
options to purchase an aggregate of 150,000 shares of the Company’s
common stock. These equity awards were granted under the Savara
Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule
5635(c)(4) of the NASDAQ Listing Rules as an inducement material to
the employees’ acceptance of employment with the Company.
The options have an exercise price of $3.57 per share, the
closing trading price of the Company's common stock on the NASDAQ
Global Market on the grant date. Each option has a 10-year term and
vests as to 1/16th of the number of shares subject to the option on
each quarterly anniversary of the employee’s first day of
employment, subject to the employee’s continued employment on each
such vesting date.
About Savara
Savara is a clinical stage biopharmaceutical company focused on
rare respiratory diseases. Our lead program, molgramostim nebulizer
solution, is an inhaled granulocyte-macrophage colony-stimulating
factor (GM-CSF) in Phase 3 development for autoimmune pulmonary
alveolar proteinosis (aPAP). Molgramostim is delivered via an
investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our
management team has significant experience in rare respiratory
diseases and pulmonary medicine, identifying unmet needs, and
effectively advancing product candidates to approval and
commercialization. More information can be found at
www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn:
www.linkedin.com/company/savara-pharmaceuticals/).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230804265923/en/
Savara Inc. IR & PR Anne Erickson
(anne.erickson@savarapharma.com) (512) 851-1366
Savara (NASDAQ:SVRA)
過去 株価チャート
から 4 2024 まで 5 2024
Savara (NASDAQ:SVRA)
過去 株価チャート
から 5 2023 まで 5 2024